ZimVie Inc. - ZIMV STOCK NEWS

ZimVie Inc. (Nasdaq: ZIMV) has launched its latest educational facility, the ZimVie Institute South, in Palm Beach Gardens, Florida. This state-of-the-art center spans over 11,000 sq. ft. and is designed for hands-on dental training. It features advanced training spaces including life-like simulated patient models, a cadaver lab, and a fully integrated digital workflow incorporating 3D printing and RealGUIDE™ software.

The facility aims to enhance professional development for dental practitioners, with plans to accommodate over 1,500 dental professionals annually. ZimVie currently trains over 100,000 dental professionals worldwide through its six institutes and virtual programs. This initiative reflects ZimVie’s commitment to leading advancements in dental education and innovation.

ZimVie has launched two new dental biomaterials, the RegenerOss CC Allograft Particulate and RegenerOss Bone Graft Plug, expanding its portfolio of bone graft solutions for dental applications. These products aim to fill bony voids and assist in dental procedures, enhancing ZimVie's presence in the dental biomaterials market. The RegenerOss solutions complement ZimVie's existing Puros Allograft line, which is known for its clinical efficacy. Indraneel Kanaglekar, SVP and President of ZimVie Dental, emphasized the company’s commitment to innovation and expanding its product offerings to meet customer needs.

Founded in March 2022, ZimVie focuses on the dental and spine markets and serves customers in over 70 countries with an extensive portfolio of clinically supported products.

ZimVie Inc. (Nasdaq: ZIMV) will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results. Interested participants can register in advance to listen to the call, and an archived replay will be available afterwards on the company’s investor relations website. Founded as a spin-off from Zimmer Biomet in March 2022, ZimVie specializes in the dental and spine markets, providing a range of innovative products aimed at treating spine pathologies and aiding dental procedures. With operations in over 70 countries, ZimVie aims to leverage extensive clinical evidence to support its diversified product portfolio.

ZimVie Inc. announced the French government's approval for Mobi-C Cervical Disc reimbursement, enhancing access to this treatment in both public and private sectors as of April 3, 2023. Furthermore, the product received a top quality rating of 10A* from the Orthopaedic Data Evaluation Panel in the UK, indicating strong clinical evidence supporting its performance. Mobi-C, a leading cervical disc replacement device, has been in use since 2004, and its reimbursement is expected to increase adoption among surgeons, as noted by Dr. Thierry Dufour in Paris. This approval addresses financial barriers and underscores the product's credibility in the medical community.

ZimVie Inc. (Nasdaq: ZIMV) announced the publication of a study in The International Journal of Oral & Maxillofacial Implants, highlighting the favorable properties of its Puros Cancellous Particulate Allograft. This allograft exhibited a collagen microstructure and surface area 100 times greater than freeze-dried allografts, leading to a significantly higher response from mesenchymal stromal cells (hBMSC) in vitro. ZimVie’s Puros portfolio has been utilized for over 20 years, backed by over 300 peer-reviewed publications, establishing it as a leading choice in dental implants.

ZimVie Inc. (Nasdaq: ZIMV) announces that Highmark and BCBS North Dakota have deemed the Tether™ device as medically necessary for treating pediatric scoliosis. Effective January 30, 2023, and March 6, 2023, respectively, the new policies expand eligibility for vertebral body tethering (VBT) to over 4 million and 280,000 patients. The Tether™ is the only FDA-approved device for VBT, with over 1,300 applications since its humanitarian device exemption in August 2019. Experts indicate these developments highlight advancements in VBT technology, allowing more children to access crucial treatment within their growth window.

ZimVie Inc. (Nasdaq: ZIMV) reported its FY 2022 financial results, with third-party net sales of $909.5 million, reflecting a 9.8% decline compared to FY 2021. The company recorded a net loss of ($63.9 million) and a net loss margin of (7.0%). Adjusted net income rose to $47.9 million with adjusted diluted EPS at $1.84. The fourth quarter saw net sales of $228.2 million, down 12.4% year-over-year. Key developments included new product launches, an expanded policy decision affecting 4+ million lives, and a successful ERP transition. Guidance for FY 2023 predicts net sales between $825 million and $850 million.

ZimVie Inc. (Nasdaq: ZIMV) announced advancements in its digital dentistry platform with the launch of two new modules: the RealGUIDE CAD and FULL SUITE. The CAD module enhances restorative workflows with advanced design capabilities, allowing users to create complex dental structures easily. The FULL SUITE integrates existing modules into a comprehensive system, facilitating collaborative implant planning and guided surgery. These innovations will debut at LMT Lab Day in Chicago and expand to Europe at the International Dental Show next month. This strategic enhancement aims to streamline operations for dental practices and support successful patient outcomes.

ZimVie Inc. (Nasdaq: ZIMV) announced it will report its financial results for the fourth quarter and full year 2022 on March 1, 2023, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Interested parties can register for the call. ZimVie specializes in dental and spine markets and became an independent entity in March 2022, focusing on its product portfolio to serve customers in over 70 countries.